Jiangsu Hengrui Pharmaceuticals (01276) plans to repurchase 1-2 billion RMB worth of A-shares.

26/08/2025

Hengrui Medicine (01276) announced that, based on confidence in the company's future development prospects and fundamentals, measures will be taken to safeguard the company...

Jiangsu Hengrui Pharmaceuticals (01276) has announced that, based on confidence in the company's future development prospects and fundamental strengths, and in order to safeguard the interests of the company and its vast number of investors, the company will improve its long-term incentive mechanism for employees. In order to fully motivate employees, the company plans to repurchase its A shares using its own funds. The total amount of funds to be used for the repurchase will not be less than 1 billion yuan and not exceed 2 billion yuan. The repurchase price will not exceed 90.85 yuan per share. The repurchased shares will be used for the A share employee stock ownership plan.

Macau L.J. (01680) issues profit warning, expecting a decrease of approximately 12% in the total reported earnings for the mid-term compared to the same period last year.

BAIC MOTOR (01958) released its interim results, with a net profit attributable to shareholders of 360 million yuan, a year-on-year decrease of 81.8%.

ZIBUYU (02420) announces its interim results, with a net profit attributable to shareholders of approximately 1.06 billion yuan, an increase of 15.9% year-on-year.

Macau L.J. (01680) issues profit warning, expecting a decrease of approximately 12% in the total reported earnings for the mid-term compared to the same period last year.

BAIC MOTOR (01958) released its interim results, with a net profit attributable to shareholders of 360 million yuan, a year-on-year decrease of 81.8%.

ZIBUYU (02420) announces its interim results, with a net profit attributable to shareholders of approximately 1.06 billion yuan, an increase of 15.9% year-on-year.